Stocks Health care ELTX
NASDAQ · Health careElicio Therapeutics, Inc. (ELTX)
It posted a net loss of $37.8M. In fiscal 2025 capital spending exceeded operating cash flow by $37M. At June 30, 2026 it held $23.5M in cash against $9.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Elicio Therapeutics, Inc.
- Net worth
- Elicio Therapeutics, Inc. has a market value (market cap) of $42.3M at the latest share price, and shareholders' equity of $7.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $2.3M (-91.9% year on year), with a net loss of $28.2M.
- Cash flow
- In fiscal 2025 operations used $37M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Elicio Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Elicio Therapeutics, Inc. does
Elicio Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ELTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$39.6M | -$2.58 | -$37M |
| 2024 | n/a | -$51.9M | -$4.25 | -$37.2M |
| 2023 | n/a | -$35.2M | -$6.96 | -$32.8M |
| 2022 | $2.3M | -$28.2M | -$89.27 | -$22.8M |
| 2021 | $28.3M | -$54.6M | -$133.56 | -$53M |
| 2021 | $2.9M | -$80.1M | -$375.76 | -$22.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Elicio Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- August 13, 2026
- August 13, 2026
- July 16, 2026Passive stake (5% or more) SCHEDULE 13G
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- July 2, 2026
- June 24, 2026
- June 17, 2026Other event 8-K
- June 15, 2026Other event 8-K
- May 11, 2026
Insider trades
What the people running Elicio Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| February 2, 2026 | Haqq ChristopherSee Remarks | Received as pay | 25,400 | - |
| February 2, 2026 | DeMuth PeterChief Scientific Officer | Received as pay | 20,800 | - |
| February 2, 2026 | Shah PreetamSee Remarks | Received as pay | 24,000 | - |
| February 2, 2026 | Connelly RobertCEO, President and Director, Director | Received as pay | 73,600 | - |
| December 9, 2025 | DeMuth PeterChief Scientific Officer | Exercised options | 362 | $1.6K |
Who owns ELTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Yekaterina Chudnovsky13D, may seek influence with 1 related filers | 48% | June 4, 2025 |
| Moti Investments LLC13G, passive | 6.1% | July 16, 2026 |
| Knoll Capital Management, LLC13G, passive with 2 related filers | 5.3% | July 8, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 48 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Knoll Capital Management, LLC | 1,211,957 | +581,042 |
| BlackRock, Inc. | 766,005 | +715,408 |
| Vanguard Capital Management LLC | 572,151 | +53,513 |
| Geode Capital Management, LLC | 311,354 | +176,190 |
| State Street Corp | 179,420 | +128,800 |
| Northern Trust Corp | 130,162 | +70,428 |
| Ikarian Capital, LLC | 100,000 | new |
| Vanguard Portfolio Management LLC | 88,905 | new |
| Vanguard Fiduciary Trust Co | 88,062 | +18,873 |
| Alliancebernstein L.P. | 81,280 | new |
| UBS Group AG | 40,419 | +6,650 |
| Charles Schwab Investment Management Inc | 31,706 | new |
| Boothbay Fund Management, LLC | 30,690 | new |
| Morgan Stanley | 25,546 | -6,858 |
| Leonteq Securities AG | 20,000 | new |
| Nuveen, LLC | 17,888 | new |
| Citigroup Inc | 17,726 | new |
| Bank of New York Mellon Corp | 15,884 | new |
| New York State Common Retirement Fund | 14,200 | new |
| Meyer Handelman Co | 13,899 | 0 |
Insiders
4 insiders reported holding 223,494 shares in total, about $359.8K at the last price.
| Holder | Shares |
|---|---|
| Connelly RobertCEO, President and Director, Director | 120,570 |
| Haqq ChristopherSee Remarks | 57,381 |
| Shah PreetamSee Remarks | 24,000 |
| DeMuth PeterChief Scientific Officer | 21,543 |
Questions about ELTX
What does Elicio Therapeutics, Inc. do?
Elicio Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ELTX. Its shares trade on NASDAQ under the ticker ELTX.
What is Elicio Therapeutics, Inc.'s net worth?
Elicio Therapeutics, Inc. has a market value (market cap) of $42.3M at the latest share price, and shareholders' equity of $7.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Elicio Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $37.8M.
When did Elicio Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder nomination deadline from September 14, 2026.
When is Elicio Therapeutics, Inc.'s next earnings report?
Elicio Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ELTX with
Follow ELTX
Get an email when Elicio Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Elicio Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.